A Comparative Study of Aleglitazar and Actos in Patients With Type 2 Diabetes Mellitus and Class II Heart Failure.

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Hoffmann-La Roche
ClinicalTrials.gov Identifier:
NCT00461058
First received: April 16, 2007
Last updated: July 7, 2014
Last verified: July 2014
  Purpose

This 2 arm study will compare the safety, tolerability and efficacy of aleglitaz ar and Actos in patients with type 2 diabetes and symptomatic NYHA class II hear t failure. Eligible patients will be randomized to receive either aleglitazar, t itrated to an individual maximum tolerated dose up to 0.3mg p.o. daily, or Actos

, titrated to an individual maximum tolerated dose up to 45mg p.o. daily, in add ition to prescribed diabetes therapy where applicable. The anticipated time on s tudy treatment is 3-12 months, and the target sample size is 100-500 individuals


Condition Intervention Phase
Diabetes Mellitus, Type 2
Drug: aleglitazar
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
Official Title: A Randomized, Double Blind Study to Compare the Safety and Tolerability of Aleglitazar and Actos in Patients With Type 2 Diabetes and NYHA Class II Heart Failure.

Resource links provided by NLM:


Further study details as provided by Hoffmann-La Roche:

Primary Outcome Measures:
  • Incidence of cardiovascular death, hospitalization or clinic visit for heart failure with i.v. administration of diuretics during 26 week treatment period. [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Safety: peripheral oedema, deterioration of heart failure, increase in body weight during 26 week treatment period., AEs, lab. parameters. Efficacy: Change from baseline to week 26 in HbAlc, FPG, FPI and lipid profile. [ Designated as safety issue: No ]

Enrollment: 14
Study Start Date: May 2007
Study Completion Date: February 2008
Primary Completion Date: February 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1 Drug: aleglitazar
1

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • adult patients, >=18 years of age;
  • type 2 diabetes for >=1 month;
  • drug naive, or receiving stable doses of <=2 oral antihyperglycemic medications;
  • HbAlc 6.5-10.0% at screening;
  • symptomatic, stable NYHA class 2 heart failure at screening.

Exclusion Criteria:

  • type 1 diabetes;
  • current or previous treatment with insulin;
  • uncontrolled hypertension;
  • NYHA class 1, 3 or 4 at screening.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00461058

  Hide Study Locations
Locations
United States, Arkansas
Jonesboro, Arkansas, United States, 72401
United States, California
Carmichael, California, United States, 95608
Loma Linda, California, United States, 92354
Long Beach, California, United States, 90822
United States, Florida
Jacksonville, Florida, United States, 32216
United States, Louisiana
Slidell, Louisiana, United States, 70458
United States, Minnesota
Minneapolis, Minnesota, United States, 55455
United States, Ohio
Cleveland, Ohio, United States, 44195
United States, Oklahoma
Oklahoma City, Oklahoma, United States, 73112
Tulsa, Oklahoma, United States, 74104
Israel
Ashkelon, Israel, 78278
Haifa, Israel, 31096
Kfar Saba, Israel, 44281
Mexico
Culiacan, Mexico, SIN80020
Guadalajara, Mexico, JAL44340
Metepec, Mexico, EMEX52140
Mexico City, Mexico, DF7060
Mexico City, Mexico, 11650
Monterrey, Mexico, 64000
Pachuca, Mexico, 42000
San Luis Potosi, Mexico, SLP78250
Romania
Arad, Romania, 310037
Bacau, Romania, 600114
Baia Mare, Romania, 430123
Bucuresti, Romania, 20475
Bucuresti, Romania, 010242
Bucuresti, Romania, 50452
Oradea, Romania, 410169
Ploiesti, Romania, 100097
Targoviste, Romania, 130083
Russian Federation
Moscow, Russian Federation, 127299
Moscow, Russian Federation, 123436
Moscow, Russian Federation, 125101
Moscow, Russian Federation, 127018
Saratov, Russian Federation, 410028
St Petersburg, Russian Federation, 198205
St Petersburg, Russian Federation, 199106
St Petersburg, Russian Federation, 191025
Yaroslavl, Russian Federation, 150062
Ukraine
Donetsk, Ukraine, 83114
Donetsk, Ukraine, 83003
Kharkov, Ukraine, 61178
Kiev, Ukraine, 2091
Kiev, Ukraine, 02091
Kiev, Ukraine, 1151
Sponsors and Collaborators
Hoffmann-La Roche
Investigators
Study Director: Clinical Trials Hoffmann-La Roche
  More Information

No publications provided

Responsible Party: Hoffmann-La Roche
ClinicalTrials.gov Identifier: NCT00461058     History of Changes
Other Study ID Numbers: BC20265
Study First Received: April 16, 2007
Last Updated: July 7, 2014
Health Authority: United States: Food and Drug Administration

Additional relevant MeSH terms:
Diabetes Mellitus
Diabetes Mellitus, Type 2
Heart Failure
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Heart Diseases
Cardiovascular Diseases

ClinicalTrials.gov processed this record on July 24, 2014